Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.

Clark JI, Singh J, Ernstoff MS, Lao CD, Flaherty LE, Logan TF, Curti B, Agarwala SS, Taback B, Cranmer L, Lutzky J, Luna TL, Aung S, Lawson DH.

J Immunother Cancer. 2018 Jul 27;6(1):76. doi: 10.1186/s40425-018-0387-x.

2.

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.

Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP.

J Immunother Cancer. 2017 Dec 19;5(1):102. doi: 10.1186/s40425-017-0307-5.

3.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL.

J Clin Oncol. 2018 Jun 10;36(17):1658-1667. doi: 10.1200/JCO.2017.73.7379. Epub 2017 Oct 5.

4.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, Maio M, Urba WJ, Gangadhar TC, Suryawanshi S, Neely J, Jure-Kunkel M, Krishnan S, Kohrt H, Sznol M, Levy R.

Clin Cancer Res. 2017 Apr 15;23(8):1929-1936. doi: 10.1158/1078-0432.CCR-16-1272. Epub 2016 Oct 18.

5.

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.

Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP.

Cancer Immunol Immunother. 2016 Dec;65(12):1533-1544. Epub 2016 Oct 6.

6.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS.

Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270.

7.

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ.

Lancet Oncol. 2016 Mar;17(3):378-88. doi: 10.1016/S1470-2045(15)00515-X. Epub 2016 Jan 13.

PMID:
26794930
8.

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH Jr, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, Figlin RA.

J Immunother Cancer. 2015 Apr 21;3:14. doi: 10.1186/s40425-015-0055-3. eCollection 2015.

9.

Whole-body PET/CT evaluation of tumor perfusion using generator-based 62Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II): validation by direct comparison to 15O-water in metastatic renal cell carcinoma.

Fletcher JW, Logan TF, Eitel JA, Mathias CJ, Ng Y, Lacy JL, Hutchins GD, Green MA.

J Nucl Med. 2015 Jan;56(1):56-62. doi: 10.2967/jnumed.114.148106. Epub 2014 Dec 18.

10.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ.

J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.

11.

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB.

Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

12.

Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.

Bradish JR, Richey JD, Post KM, Meehan K, Sen JD, Malek AJ, Katona TM, Warren S, Logan TF, Fecher LA, Cheng L.

Mod Pathol. 2015 Apr;28(4):480-6. doi: 10.1038/modpathol.2014.136. Epub 2014 Nov 7.

13.

Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.

Logan TF.

Curr Oncol Rep. 2013 Apr;15(2):83-90. doi: 10.1007/s11912-013-0299-3. Review.

PMID:
23408121
14.

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.

J Clin Oncol. 2013 Jan 10;31(2):181-6. doi: 10.1200/JCO.2012.43.3383. Epub 2012 Dec 3.

15.

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.

Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R.

J Transl Med. 2012 Nov 21;10:236. doi: 10.1186/1479-5876-10-236.

16.

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS.

Lancet Oncol. 2012 May;13(5):459-65. doi: 10.1016/S1470-2045(12)70090-6. Epub 2012 Mar 27.

PMID:
22456429
17.

Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.

Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, Krygowski M, Cincotta M, Shapiro M, Duran I, Berkenblit A.

J Clin Oncol. 2011 May 1;29(13):1750-6. doi: 10.1200/JCO.2010.29.2235. Epub 2011 Mar 28.

PMID:
21444868
18.

A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.

Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, Bell WN, Thurmond LM, Weisenbach J, Dar MM.

Clin Cancer Res. 2008 Jun 1;14(11):3462-9. doi: 10.1158/1078-0432.CCR-07-4740.

19.

Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.

Clark JI, Mehrabi J, Sosman JA, Logan TF, Margolin KA, Dutcher JP, Urba WJ, Ernstoff MS, McDermott DF, Lau AM, Atkins MB.

J Immunother. 2007 Nov-Dec;30(8):839-46.

PMID:
18049336
20.

Urticaria and angioedema in renal cell cancer patients treated with IL-2.

Logan TF, Strippoli G, Levine MI.

Cancer Invest. 2007;25(7):584-8.

PMID:
17852118
21.

Interleukins 18 and 21: biology, mechanisms of action, toxicity, and clinical activity.

Logan TF, Robertson MJ.

Curr Oncol Rep. 2006 Mar;8(2):114-9. Review.

PMID:
16507221
22.

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.

Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF.

J Clin Oncol. 2005 Oct 20;23(30):7660-8. Erratum in: J Clin Oncol. 2006 Aug 20;24(24):4047.

PMID:
16234528
24.

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB.

J Clin Oncol. 2005 Jan 1;23(1):133-41. Erratum in: J Clin Oncol. 2005 Apr 20;23(12):2877.

PMID:
15625368
25.

The systemic treatment of advanced cutaneous melanoma.

Logan TF.

Facial Plast Surg Clin North Am. 2003 Feb;11(1):75-85. Review. No abstract available.

PMID:
15062290
26.

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML.

J Clin Oncol. 2004 Mar 1;22(5):909-18.

PMID:
14990647
27.

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA.

J Clin Oncol. 2003 Aug 15;21(16):3133-40. Epub 2003 Jun 16.

PMID:
12810695
28.

MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.

Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Brusic V, Sidney J, Sette A, Logan TF, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ.

Clin Cancer Res. 2003 Mar;9(3):947-54.

29.

Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.

Nelson RP Jr, Logan TF, Abonour R.

Bone Marrow Transplant. 2002 Dec;30(12):805-12. Review.

30.

Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial.

Logan TF, Jadali F, Egorin MJ, Mintun M, Sashin D, Gooding WE, Choi Y, Bishop H, Trump DL, Gardner D, Kirkwood J, Vlock D, Johnson C.

Cancer Chemother Pharmacol. 2002 Dec;50(6):433-44. Epub 2002 Oct 1.

PMID:
12451469
31.

Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: a series of six cases.

Fakih M, Schiff D, Erlich R, Logan TF.

Ann Oncol. 2001 Aug;12(8):1173-7. Review.

PMID:
11583203
32.

A painful cutaneous nodule as the presentation of metastatic transitional cell carcinoma of the renal pelvis.

Zirwas MJ, Hunt S, Logan TF, Abernethy JL, Seraly MP.

J Am Acad Dermatol. 2000 May;42(5 Pt 2):867-8.

PMID:
10767689
33.

Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy.

Logan TF, Banner B, Rao U, Ernstoff MS, Wolmark N, Whiteside TL, Miketic L, Kirkwood JM.

Clin Exp Immunol. 1998 Dec;114(3):347-54.

34.

Malignant priapism as the initial clinical manifestation of metastatic renal cell carcinoma with invasion of both corpora cavernosum and spongiosum.

Nezu FM, Dhir R, Logan TF, Lavelle J, Becich MJ, Chancellor MB.

Int J Impot Res. 1998 Jun;10(2):101. No abstract available.

PMID:
9647945
35.

Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients.

Logan TF, Gooding WE, Whiteside TL, Ernstoff MS, Kaplan SS, Miketic L, Vlock DR, Tompkins C, Wood DL, Nadler PI, Kirkwood JM.

J Immunother. 1997 Sep;20(5):387-98.

PMID:
9336746
36.
37.

Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.

Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL.

Clin Cancer Res. 1996 Aug;2(8):1263-74.

38.
39.

An application of decision theory to patient screening for an autologous tumour vaccine trial.

Shannon WD, Bryant J, Logan TF, Day R.

Stat Med. 1995 Oct 15;14(19):2099-110.

PMID:
8552889
40.

In-111 labeled leukocyte detection of metastatic renal cell carcinoma.

Kirshen M, Charron M, Logan TF.

Clin Nucl Med. 1995 Oct;20(10):945-6. No abstract available.

PMID:
8617016
41.

The pathogenesis of disseminated intravascular coagulation in sepsis.

Logan TF, Virji MA, Gooding WE, Bontempo FA, Ernstoff MS, Kirkwood JM.

JAMA. 1994 Feb 9;271(6):427-8. No abstract available.

PMID:
8295311
42.

Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer Institute.

Logan TF, Shannon W, Bryant J, Kane P, Wolmark N, Posner M, Kirkwood JM, Ernstoff MS, Futrell JW, Straw LD, et al.

Melanoma Res. 1993 Dec;3(6):451-5.

PMID:
8161884
44.

Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor.

Logan TF, Virji MA, Gooding WE, Bontempo FA, Ernstoff MS, Kirkwood JM.

J Natl Cancer Inst. 1992 Dec 2;84(23):1802-10.

PMID:
1433370
45.

Granulocytopenia in cancer patients treated in a phase I trial with recombinant human tumor necrosis factor.

Logan TF, Kaplan SS, Bryant JL, Ernstoff MS, Krause JR, Kirkwood JM.

J Immunother (1991). 1991 Apr;10(2):84-95.

PMID:
1675121
46.

Intra-abdominal actinomycosis presenting with sulfur granules in the urine.

Wajszczuk CP, Logan TF, Pasculle AW, Ho M.

Am J Med. 1984 Dec;77(6):1126-8.

PMID:
6507466

Supplemental Content

Loading ...
Support Center